All News
Filter News
Found 532 articles
-
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
4/4/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for Dupixent® 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis, a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow.
-
Sanofi inked a pact with IGM Biosciences that could pass $6 billion. However, Sanofi CEO Paul Hudson's pay had a drop of about 3.7%, according to the company’s annual filing.
-
Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
3/29/2022
Sanofi will host an Immunology Investor Event with key members of the leadership team providing updates on how the company is advancing its Immunology strategy, including the ambition to more than quadruple Immunology franchise sales by the end of the decade.
-
Dupixent (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
3/28/2022
Today sanofi-aventis Canada Inc. (Sanofi Canada) announced the expanded approval of Dupixent® (dupilumab injection) as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma.
-
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
3/26/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced that detailed positive results from the Phase 3 PRIME2 trial evaluating the efficacy and safety of Dupixent® were presented in a late-breaking session at the American Academy of Dermatology 2022 Annual Meeting.
-
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
3/26/2022
Detailed positive results from the Phase 3 PRIME2 trial evaluating the safety and efficacy of Dupixent® was presented in a late-breaking session at the American Academy of Dermatology 2022 Annual Meeting.
-
Vaxxinity Appoints Dr. Peter Powchik to Board of Directors
3/21/2022
Vaxxinity, Inc. today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity’s Executive Vice President, Research & Development.
-
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting
3/21/2022
AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, in Boston.
-
AstraZeneca’s Fasenra hit a roadblock after the FDA issued a Complete Response Letter for chronic rhinosinusitis with nasal polyps (CRSwNP).
-
Eosinophilic Asthma Treatment Market: The nasal segment is projected to be driven by increase in the use of nasal sprays for the treatment of asthma
3/3/2022
Albany NY, United States: Asthma associated with high level of eosinophils is known as eosinophilic asthma.
-
In 2021, Sanofi earned about $4.2 billion from Dupixent sales, and Regeneron earned about $1.8 billion.
-
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
2/28/2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
-
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
2/28/2022
Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
-
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
2/26/2022
Positive detailed results from a second Phase 3 trial showed that Dupixent® 300 mg weekly significantly improved the signs and symptoms of eosinophilic esophagitis at 24 weeks compared to placebo in patients 12 years and older.
-
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
2/26/2022
Detailed results from a Phase 3 trial showed that adding Dupixent® to standard-of-care antihistamines significantly reduced itch and hives at 24 weeks in biologic-naïve patients with chronic spontaneous urticaria compared to antihistamines alone in this investigational setting.
-
After roaring into February with positive data in five different indications, Regeneron and Sanofi announced today a late-stage Dupixent trial has been halted due to futility.
-
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
2/18/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced a Phase 3 trial evaluating Dupixent® in patients with chronic spontaneous urticaria will stop due to futility, based on a pre-specified interim analysis.
-
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
2/18/2022
A Phase 3 trial evaluating Dupixent® in patients with chronic spontaneous urticaria, who were refractory to omalizumab, will stop due to futility based on a pre-specified interim analysis.
-
Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
2/11/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from its Phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).